A San Diego-based developer of targeted cancer drugs is hoping its medicine can shrink tumors in non-small cell lung cancer caused by specific genetic alterations.
STAT Plus: Watch this company: Turning Point Therapeutics shares pop 57% after IPO
News
STAT Plus: ‘The largest application we can imagine’: Illumina and Grail CEOs defend their deal to investors
The CEOs of the two companies told STAT it would take time for investors to understand the advantages of combining the two firms. […]
News
STAT Plus: With Grail in its sights, Illumina pursues grand vision that could reshape the business of cancer diagnoses
With Grail in its sights, Illumina pursues grand vision that could reshape the business of cancer diagnoses. […]
News
STAT Plus: Halozyme?s lead drug fails; company will cut 55% of workforce in bid for profitability
Halozyme, a San Diego-based biotech, said that its lead drug, for pancreatic cancer, had failed to extend the lives of patients in a clinical trial. […]
